Welcome to our dedicated page for Adverum Biotech news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotech stock.
Adverum Biotechnologies, Inc. (ADVM) generated a stream of news as a clinical-stage gene therapy company focused on highly prevalent ocular diseases, particularly neovascular or wet age-related macular degeneration (wet AMD). Company releases consistently describe Adverum’s goal of establishing intravitreal gene therapy as a new standard of care, using durable, single-administration treatments to preserve sight and potentially prevent blindness.
News coverage for ADVM has centered on the development of its lead gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly ADVM-022). Updates have included milestones in the pivotal Phase 3 ARTEMIS trial for wet AMD, such as initiation, screening progress, and the completion of target enrollment of 284 patients, as reported in SEC filings and press releases. Additional articles have highlighted long-term follow-up data from earlier studies like OPTIC and LUNA, as well as scientific presentations on Ixo-vec biodistribution and aflibercept expression in the eye.
Investors following ADVM-related news can also see announcements about regulatory designations for Ixo-vec, including Fast Track and RMAT status from the U.S. FDA, PRIME designation from the European Medicines Agency, and the Innovation Passport in the UK. Corporate updates have covered financing activities, inducement equity grants under the 2017 Inducement Plan, and participation in ophthalmology conferences.
A major theme in later news is the strategic transaction with Eli Lilly and Company. Releases dated October and December 2025 detail Lilly’s tender offer to acquire all outstanding Adverum shares for cash plus a non-tradable contingent value right (CVR), and the subsequent expiration and completion of the tender offer with all conditions satisfied. This news page therefore serves both as a record of Adverum’s clinical and corporate developments and as an archive of announcements leading up to and including its acquisition by Lilly.
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, announced its participation in TD Cowen’s Genetic Medicines & RNA Summit.
Laurent Fischer, M.D., the company's president and CEO, will engage in a fireside chat at the summit on June 21, 2024, at 10:00 a.m. ET.
The event will be webcasted live and accessible via Adverum's website under the Investors section, with a replay available for at least 30 days post-event.
Adverum Biotechnologies announced the appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Board Member, effective June 11, 2024. Dr. Ozden, with over 20 years in ophthalmology drug development, transitions from the board to the executive team, bringing her expertise in clinical development and gene therapies. Dr. Kiss, an experienced retina specialist and gene therapy expert, will fill Ozden's vacated board seat. Their contributions are expected to advance Adverum's Ixo-vec gene therapy for wet AMD, particularly through the LUNA trial and pivotal studies.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) reported Q1 2024 financial results and pipeline highlights, showcasing strong cash position, positive preliminary data from the LUNA trial, and upcoming milestones. The company presented a 26-week interim analysis at ASRS on Ixo-vec for wet AMD, with promising reduction in injections and good tolerability. Financially, the company's cash, cash equivalents, and short-term investments increased to $193.3 million, supporting operations into late 2025.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) will participate in upcoming investor conferences in May 2024 to showcase its gene therapy for ocular diseases. The company will present at the 2024 RBC Global Healthcare Conference, BofA Securities 2024 Health Care Conference, and H.C. Wainwright 2nd Annual BioConnect Investor Conference. Investors can access the webcast on Adverum's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Adverum Biotech (ADVM)?
What is the market cap of Adverum Biotech (ADVM)?
